Erasca, Inc.

Erasca, Inc.

ERAS · Nasdaq

Erasca, Inc. (ERAS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Erasca, Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 84 days

EPS estimate

-0.12

Revenue estimate

0

Past earnings

11 Aug 2026
EPS actual
-0.14 (-25.7%)
estimate -0.11
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 May 2026
EPS actual
-0.60 (-475.3%)
estimate -0.10
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
—
estimate -0.10
Revenue actual
—
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Mar 2026
EPS actual
-0.10 (+6.5%)
estimate -0.11
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.11 (-6.2%)
estimate -0.10
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Erasca, Inc. missed consensus on EPS, with EPS of -$0.14 versus an estimate of -$0.1114, while revenue met expectations at $0. In the prior quarter EPS also missed estimates and revenue likewise met expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Jonathan E. Lim
Employees
103
IPO date
16 Jul 2021
ISIN
US29479A1088
Website
erasca.com

Frequently asked questions

When does Erasca, Inc. (ERAS) next report earnings?

Erasca, Inc. (ERAS) is scheduled to report earnings on November 11, 2026.

What was Erasca, Inc.'s most recent earnings date?

Erasca, Inc. (ERAS) last reported earnings on August 11, 2026.

Where is Erasca, Inc. stock listed?

Erasca, Inc. (ERAS) is listed on Nasdaq.